Results 121 to 130 of about 38,480 (291)

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies [PDF]

open access: bronze, 2008
Pancras C. Wong   +7 more
openalex   +1 more source

Association of Anaesthetists guidelines: safe vascular access 2025

open access: yesAnaesthesia, Volume 80, Issue 11, Page 1381-1396, November 2025.
Summary Introduction Safe vascular access is integral to anaesthetic and critical care practice. However, despite technological and procedural advances, it remains a frequent source of adverse events and patient harm. Ensuring a safe and effective approach to the selection, insertion and care of vascular access devices should be a priority for all ...
Andrew J. Johnston   +13 more
wiley   +1 more source

Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 137, Issue 5, November 2025.
ABSTRACT The type of prescriber typically fulfils the criteria for confounding, as it is associated both with the exposure (e.g., prescriber types may differ in their choice of first‐line treatment) and with the outcome (as different types of prescribers often treat patients with different disease severity).
Saad Hanif Abbasi   +4 more
wiley   +1 more source

Apixaban versus enoxaparin to prevent venous thromboembolism in post-operative patients with gynecologic cancers at an urban academic medical center

open access: yesGynecologic Oncology Reports
Objective: A recent clinical trial demonstrated that the use of apixaban was safe and equal to enoxaparin (LMWH) in post-operative gynecologic oncology patients.
Victoria Diamond   +5 more
doaj   +1 more source

Letter to the Editor: Pharmacokinetics of apixaban [PDF]

open access: yesAustralian Prescriber, 2017
Penny Beirne, Paul Chin, Matthew Doogue
openaire   +3 more sources

Apixaban-Induced Skin Purpura

open access: yesAnnals of Geriatric Medicine and Research, 2021
Miryam Moreta-Rodríguez   +3 more
openaire   +5 more sources

Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials [PDF]

open access: yes, 2015
The coagulation system contributes greatly to the evolution of myocardial infarction (MI). Anticoagulation may reduce the occurrence of MI as monotherapy or with con- comitant use of aspirin.
Aradi, Dániel   +3 more
core  

Clinical associations and prognosis in Asian and European patients with symptom‐controlled atrial fibrillation: Insights from two prospective registries in Europe and Asia

open access: yesEuropean Journal of Clinical Investigation, Volume 55, Issue 11, November 2025.
Symptom‐controlled atrial fibrillation (AF), defined as asymptomatic or with mild symptoms according to the European Heart Rhythm Association (EHRA) score, was more common among Asians than in Europeans. In Asians, comorbidities of diabetes, hypertension, and prior ischemic stroke increase the likelihood of being scAF.
Wee Siong Teo   +9 more
wiley   +1 more source

Patient Characteristics, Healthcare Contacts and Drug Use in Polycythaemia Vera in Denmark

open access: yesEuropean Journal of Haematology, Volume 115, Issue 5, Page 474-483, November 2025.
ABSTRACT Objective Patients with polycythaemia vera (PV) may experience symptoms and cardiovascular complications before receiving a diagnosis. Understanding the associated patterns of healthcare and drug utilisation may help detect patients who need diagnostic workup.
Karoline Mathilde Lundgaard   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy